hemophilia A gene therapy (Cell Genesys)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehemophilia A gene therapy (Cell Genesys)

Drug Alias Namelentiviral vectors gene therapy (Cell Genesys/Salk)lentiviral vector technology (Cell Genesys/Salk)retroviral vectors (Cell Genesys/Salk)lentiviral vectors (Cell Genesys/Salk)

ClassificationCell and gene therapy > Cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsHemophilia ATrauma, Nervous SystemCentral Nervous System Diseases +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBiosante Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiosante Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsHemophilia ATrauma, Nervous SystemCentral Nervous System Diseases +[5]

Other Information

ATC CodeN/A